Therapeutic vaccine for chronic diseases after the COVID-19 Era.
Antibody
Epitope
Vaccine
Journal
Hypertension research : official journal of the Japanese Society of Hypertension
ISSN: 1348-4214
Titre abrégé: Hypertens Res
Pays: England
ID NLM: 9307690
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
22
04
2021
accepted:
24
04
2021
pubmed:
9
6
2021
medline:
14
9
2021
entrez:
8
6
2021
Statut:
ppublish
Résumé
There is currently a respiratory disease outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). After rapid development, RNA vaccines and adenoviral vector vaccines were approved within a year, which has demonstrated the strong impact of preventing infectious diseases using gene therapy technology. Furthermore, intensive immunological analysis has been performed to evaluate the efficiency and safety of these vaccines, potentially allowing for rapid progress in vaccine technology. After the coronavirus disease 2019 (COVID-19) era, the novel vaccine technology developed will expand to other vaccines. We have been developing vaccines for chronic diseases, such as hypertension, for >10 years. Regarding the development of vaccines against self-antigens (i.e., angiotensin II), the vaccine should efficiently induce a blocking antibody response against the self-antigen without activating cytotoxic T cells. Therefore, the epitope vaccine approach has been proposed to induce antibody production in response to a combination of a B cell epitope and exogenous T cell epitopes through major histocompatibility complex molecules. When these vaccines are established as therapeutic options for hypertension, their administration regimen, which might be a few times per year, will replace daily medication use. Thus, therapeutic vaccines for hypertension may be a novel option to control the progression of cerebrovascular diseases. Hopefully, the accumulation of immunological findings and vaccine technology advances due to COVID-19 will provide a novel concept for vaccines for chronic diseases.
Identifiants
pubmed: 34099884
doi: 10.1038/s41440-021-00677-3
pii: 10.1038/s41440-021-00677-3
pmc: PMC8184354
doi:
Substances chimiques
Autoantigens
0
COVID-19 Vaccines
0
Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1047-1053Informations de copyright
© 2021. The Author(s).
Références
Nakagami H. Development of COVID-19 vaccines utilizing gene therapy technology. Int Immunol. 2021 (in press).
Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, et al. SARS-CoV2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586:567–71.
doi: 10.1038/s41586-020-2622-0
Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369:77–81.
doi: 10.1126/science.abc1932
Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586:516.
doi: 10.1038/s41586-020-2798-3
Smith TRF, Patel A, Ramos S, Elwood D, Zhu X, Yan J, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun. 2020;20:2601.
doi: 10.1038/s41467-020-16505-0
Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586:589–93.
doi: 10.1038/s41586-020-2639-4
Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N. Engl J Med. 2020;383:2439–50.
doi: 10.1056/NEJMoa2027906
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Clinical trial group safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–15.
doi: 10.1056/NEJMoa2034577
Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med. 2020;383:1920–31.
doi: 10.1056/NEJMoa2022483
Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020;383:2427–38.
doi: 10.1056/NEJMoa2028436
Nakagami H. Design of therapeutic vaccines as a novel antibody therapy for cardiovascular diseases. J Cardiol. 2017;70:201–5.
doi: 10.1016/j.jjcc.2017.01.010
Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science. 2003;301:1374–7.
doi: 10.1126/science.1086907
Crotty S. Follicular helper CD4 T cells. Annu Rev Immunol. 2011;29:621–63.
doi: 10.1146/annurev-immunol-031210-101400
Zhang J, Wu Q, Liu Z, Wang Q, Wu J, Hu Y, et al. Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals. Nat Microbiol. 2021;6:51–8.
doi: 10.1038/s41564-020-00824-5
Harris JR, Markl J. Keyhole limpet hemocyanin (KLH): a biomedical review. Micron. 1999;30:597–623.
doi: 10.1016/S0968-4328(99)00036-0
Tenma A, Nakagami H, Tomioka H, Sakaguchi M, Ide R, Koriyama H, et al. AJP001, a novel helper T-cell epitope, induces a humoral immune response with activation of innate immunity when included in a peptide vaccine. FASEB Bioadv. 2019;1:760–72.
doi: 10.1096/fba.2019-00056
Nakamaru R, Nakagami H, Hayashi H, Sun J, Tenma A, Yamamoto K, et al. A novel angiotensin II peptide vaccine without an adjuvant in mice. J Hypertens. 2021;39:181–9.
doi: 10.1097/HJH.0000000000002597
Deodhar SD, Haas E, Goldblatt H. Production of antirenin to homologous renin and its effect of experimental renal hypertension. J Exp Med. 1964;119:425–32.
doi: 10.1084/jem.119.3.425
Michel JB, Guettier C, Philippe M, Galen FX, Corvol P, Ménard J. Active immunization against renin in normotensive marmoset. Proc Natl Acad Sci U.S.A. 1987;84:4346–50.
doi: 10.1073/pnas.84.12.4346
Michel JB, Sayah S, Guettier C, Nussberger J, Philippe M, Gonzalez MF, et al. Physiological and immunopathological consequences of active immunization of spontaneously hypertensive and normotensive rats against murine renin. Circulation. 1990;81:1899–910.
doi: 10.1161/01.CIR.81.6.1899
Qiu Z, Chen X, Zhou Y, Lin J, Ding D, Yang S, et al. Therapeutic vaccines against human and rat renin in spontaneously hypertensive rats. PLoS ONE. 2013;8:e66420.
doi: 10.1371/journal.pone.0066420
Gardiner SM, Auton TR, Downham MR, Sharp HL, Kemp PA, March JE, et al. Active immunization with angiotensin I peptide analogue vaccines selectively reduces the pressor effects of exogenous angiotensin I in conscious rats. Br J Pharm. 2000;129:1178–82.
doi: 10.1038/sj.bjp.0703178
Downham MR, Auton TR, Rosul A, Sharp HL, Sjöström L, Rushton A, et al. Evaluation of two carrier protein-angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man. Br J Clin Pharm. 2003;56:505–12.
doi: 10.1046/j.1365-2125.2003.01926.x
Brown MJ, Coltart J, Gunewardena K, Ritter JM, Auton TR, Glover JF. Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci (Lond). 2004;107:167–73.
doi: 10.1042/CS20030381
Ambühl PM, Tissot AC, Fulurija A, Maurer P, Nussberger J, Sabat R, et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens. 2007;25:63–72.
doi: 10.1097/HJH.0b013e32800ff5d6
Nakagami F, Koriyama H, Nakagami H, Osako MK, Shimamura M, Kyutoku M, et al. Decrease in blood pressure and regression of cardiovascular complications by angiotensin II vaccine in mice. PLoS ONE. 2013;8:e60493.
doi: 10.1371/journal.pone.0060493
Koriyama H, Nakagami H, Nakagami F, Osako MK, Kyutoku M, Shimamura M, et al. Long-term reduction of high blood pressure by angiotensin II DNA vaccine in spontaneously hypertensive rats. Hypertension. 2015;66:167–74.
doi: 10.1161/HYPERTENSIONAHA.114.04534
Watanabe R, Suzuki JI, Wakayama K, Maejima Y, Shimamura M, Koriyama H, et al. A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarction. Sci Rep. 2017;7:43920.
doi: 10.1038/srep43920
Wakayama K, Shimamura M, Suzuki JI, Watanabe R, Koriyama H, Akazawa H, et al. Angiotensin II peptide vaccine protects ischemic brain through reducing oxidative stress. Stroke. 2017;48:1362–8.
doi: 10.1161/STROKEAHA.116.016269
Tissot AC, Maurer P, Nussberger J, Sabat R, Pfister T, Ignatenko S, et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet. 2008;371:821–7.
doi: 10.1016/S0140-6736(08)60381-5
Chen X, Qiu Z, Yang S, Ding D, Chen F, Zhou Y, et al. Effectiveness and safety of a therapeutic vaccine against angiotensin II receptor type 1 in hypertensive animals. Hypertension. 2013;61:408–16.
doi: 10.1161/HYPERTENSIONAHA.112.201020
Camelia BG, Sadashiva K. Model of the whole rat AT1 receptor and the ligand-binding site. J Mol Model. 2006;12:325–37.
doi: 10.1007/s00894-005-0049-z
Fierens FL, Vanderheyden PM, De Backer JP, Vauquelin G. Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding. Eur J Pharm. 1999;372:199–206.
doi: 10.1016/S0014-2999(99)00205-8
Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 2001;103:904–12.
doi: 10.1161/01.CIR.103.6.904
Azegami T, Sasamura H, Hayashi K, Itoh H. Vaccination against the angiotensin type 1 receptor for the prevention of L-NAME-induced nephropathy. Hypertens Res. 2012;35:492–9.
doi: 10.1038/hr.2011.212
Wu H, Wang Y, Wang G, Qiu Z, Hu X, Zhang H, et al. A bivalent antihypertensive vaccine targeting L-type calcium channels and angiotensin AT1 receptors. Br J Pharm. 2020;177:402–19.
doi: 10.1111/bph.14875
Xu SZ, Zeng F, Lei M, Li J, Gao B, Xiong C, et al. Generation of functional ion-channel tools by E3 targeting. Nat Biotechnol. 2005;23:1289–93.
doi: 10.1038/nbt1148
Tang L, Gamal El-Din TM, Swanson TM, Pryde DC, Scheuer T, Zheng N, et al. Structural basis for inhibition of a voltage-gated Ca2
doi: 10.1038/nature19102
Yoshida S, Nakagami H, Hayashi H, Ikeda Y, Sun J, Tenma A, et al. The CD153 vaccine is a senotherapeutic option for preventing the accumulation of senescent T cells in mice. Nat Commun. 2020;11:2482.
doi: 10.1038/s41467-020-16347-w
Nakagami H. Cellular senescence and senescence-associated T cells as a potential therapeutic target. Geriatr Gerontol Int. 2020;20:97–100.
doi: 10.1111/ggi.13851